Keyphrases
Adenovirus
100%
Retargeting
100%
Ovarian Cancer
100%
Epidermal Growth Factor Receptor
100%
Cetuximab
100%
EGF Receptor
85%
Polymer Coating
42%
Virus
28%
Epidermal Growth Factor
28%
Adenoviral Transduction
28%
Clinical Trials
14%
Clinical Application
14%
Covalent Modification
14%
Adenovirus Type 5
14%
Basic Fibroblast Growth Factor (bFGF)
14%
Neutralizing Antibodies
14%
Receptor Phosphorylation
14%
Mitogen
14%
Cell Response
14%
Physicochemical Characteristics
14%
Infectivity
14%
Covalent Attachment
14%
Inflammatory Response
14%
Ovarian Cancer Cells
14%
Prolonged Survival
14%
Particle Aggregation
14%
Oncolytic Adenovirus
14%
Adhesion Formation
14%
Intraperitoneal Administration
14%
Peptide Ligand
14%
Virotherapy
14%
In Vivo Efficacy
14%
Human Ovarian Cancer
14%
Preclinical Animal Studies
14%
Can Shields
14%
Reactive Copolymer
14%
Anti-epidermal Growth Factor Receptor Antibody
14%
Pharmacology, Toxicology and Pharmaceutical Science
Adenoviridae
100%
Ovary Cancer
100%
Epidermal Growth Factor Receptor
100%
Cetuximab
100%
N (4 Methoxyphenylacetyl)dehydroalanine
57%
Epidermal Growth Factor
28%
Infection
14%
Receptor
14%
Malignant Neoplasm
14%
Human Adenovirus 5
14%
Neutralizing Antibody
14%
Fibroblast Growth Factor 2
14%
Clinical Trial
14%
Virotherapy
14%
Copolymer
14%
Side Effect
14%
Inflammation
14%
Mitogenic Agent
14%
Oncolytic Adenovirus
14%
Particle Aggregation
14%
Epidermal Growth Factor Receptor Antibody
14%